Zarxio Injection, Solution
Product Images NDC 61314-318

33 FDA label images from Sandoz Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 33 technical images submitted to the FDA as part of the official labeling for Zarxio (NDC 61314-318). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sandoz Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig-a (Zarxio 01)

Fig-a (Zarxio 01)
An instructional diagram of a syringe illustrating components such as needle cap, needle guard, finger grips, viewing window showing label and expiration date, dose markings, conical base of plunger stopper, plunger stopper with guard wings, plunger, and plunger head.*
FDA Label Image

Fig-b (Zarxio 02)

Fig-b (Zarxio 02)
An instructional illustration showing four items in sequence: a wipe packet labeled "WIPE," a cloth or pad, a sharps disposal container labeled "SHARPS" with a biohazard symbol, and an adhesive bandage. The items appear to represent steps or components for injection site care and disposal.*
FDA Label Image

Fig-c (Zarxio 03)

Fig-c (Zarxio 03)
An illustration showing the internal components and mechanism of a prefilled syringe for injection. The diagram details the syringe barrel, plunger, needle base, and internal spring mechanism, likely representing the injection system for administering the filgrastim-sndz solution in ZARXIO.*
FDA Label Image

Fig-d (Zarxio 04)

Fig-d (Zarxio 04)
An illustration of an injection device featuring a barrel with measurement markings, a plunger, and a needle cap. The device is designed for subcutaneous or intravenous delivery of medication, consistent with injection solutions like filgrastim-sndz.*
FDA Label Image

Fig-e (Zarxio 05)

Fig-e (Zarxio 05)
An instructional illustration showing recommended injection sites on a male body for ZARXIO (filgrastim-sndz) injection. Highlighted areas include the upper arms, abdomen, and upper thighs, indicating where subcutaneous or intravenous injections can be administered.*
FDA Label Image

Fig-f (Zarxio 06)

Fig-f (Zarxio 06)
Illustration showing the recommended injection sites for ZARXIO (filgrastim-sndz) injection. The sites highlighted include the upper arm, abdomen, and upper thigh, indicating possible areas for subcutaneous or intravenous injection.*
FDA Label Image

Fig-g (Zarxio 07)

Fig-g (Zarxio 07)
An instructional illustration showing one hand holding a syringe and the other hand removing a protective cap from the syringe needle, indicated by an upward arrow. This diagram likely demonstrates a step in preparing the ZARXIO injection, filgrastim-sndz, for intravenous or subcutaneous administration.*
FDA Label Image

Fig-h (Zarxio 08)

Fig-h (Zarxio 08)
Illustration showing how to prepare a syringe for injection of ZARXIO (filgrastim-sndz), including steps to remove the needle cap by pulling it straight off before administering the injection.*
FDA Label Image

Fig-i (Zarxio 09)

Fig-i (Zarxio 09)
An instructional illustration showing how to set the dose on a syringe injector for ZARXIO (filgrastim-sndz) injection. It depicts two hands adjusting the plunger with arrows and close-up views of the dose number settings (0.3, 0.4, 0.5 mL) marked on the syringe barrel, explaining the initial position and partial dose setting steps.*
FDA Label Image

Fig-j (Zarxio 10)

Fig-j (Zarxio 10)
An instructional line drawing showing a hand holding a syringe to administer an injection into the finger of the other hand. This likely illustrates the subcutaneous or intravenous injection technique for ZARXIO (filgrastim-sndz) injection solution.*
FDA Label Image

Fig-k (Zarxio 11)

Fig-k (Zarxio 11)
An instructional line drawing showing a hand holding a syringe for injection and the fingers preparing the injection site by stretching the skin. A magnified inset highlights details of the syringe and fingers positioning for subcutaneous or intravenous injection.*
FDA Label Image

Fig-l (Zarxio 12)

Fig-l (Zarxio 12)
An instructional line drawing illustrating the proper hand positioning for administering an injection with a syringe, showing a hand holding the syringe and preparing to inject into the skin.*
FDA Label Image

Fig-m (Zarxio 13)

Fig-m (Zarxio 13)
Illustration showing a hand holding a syringe-type device and preparing or modifying a component, likely related to the administration of ZARXIO filgrastim-sndz injection solution. The image depicts detailed fingers manipulating the syringe parts, suggesting an instructional usage step.*
FDA Label Image

Fig-n (Zarxio 14)

Fig-n (Zarxio 14)
An instructional illustration showing a hand disposing of a syringe into a container labeled 'SHARPS' with a biohazard symbol, depicting proper disposal of injection sharps. This is relevant for ZARXIO filgrastim-sndz injection solution usage.*
FDA Label Image

Fig-o (Zarxio 15)

Fig-o (Zarxio 15)
Zarxio (filgrastim-sndz) Injection, 300 mcg per 0.5 mL single-dose prefilled syringe, labeled for subcutaneous or intravenous use. The label notes absence of preservatives, refrigeration requirement, and caution about natural rubber latex. Manufactured by Sandoz Inc., a Novartis company.*
FDA Label Image

Fig-v-a (Zarxio 16)

Fig-v-a (Zarxio 16)
Zarxio (filgrastim-sndz) injection, solution in 480 mcg/0.8 mL strength for subcutaneous or intravenous use. The label indicates a single-dose prefilled syringe with needle guard. Manufactured by Sandoz Inc., the product is a recombinant Granulocyte Colony-Stimulating Factor derived from E. coli and contains no preservative.*
FDA Label Image

Fig-v-b1 (Zarxio 17)

Fig-v-b1 (Zarxio 17)
An illustration diagram of a disposable syringe showing labeled parts including the needle cap, syringe barrel with markings, and plunger, without brand-specific details.*
FDA Label Image

Fig-v-b2 (Zarxio 18)

Fig-v-b2 (Zarxio 18)
An instructional illustration showing four items used for injection care: two wipes, a cotton ball, adhesive bandages, and a sharps disposal container. Each item is labeled clearly with simple black and white line artwork.*
FDA Label Image

Fig-v-c (Zarxio 19)

Fig-v-c (Zarxio 19)
An instructional illustration showing how to remove a cap and peel off a label from a small vial, representing steps likely related to preparing an injection vial for use.*
FDA Label Image

Fig-v-d1 (Zarxio 20)

Fig-v-d1 (Zarxio 20)
A black-and-white instructional illustration showing hands attaching or removing a needle cap from a syringe. The syringe is held vertically with arrows indicating movement direction of the cap. The image demonstrates a step in preparing an injection, relevant to ZARXIO (filgrastim-sndz) injection administration.*
FDA Label Image

Fig-v-d2 (Zarxio 21)

Fig-v-d2 (Zarxio 21)
An instructional illustration showing a hand discarding a syringe cap into a sharps disposal container, indicating proper disposal of injection equipment for safety.*
FDA Label Image

Fig-v-e (Zarxio 22)

Fig-v-e (Zarxio 22)
An instructional illustration showing two hands preparing an injection. One hand holds a vial, while the other hand inserts a syringe needle vertically into the vial, indicating the drawing of medication into the syringe.*
FDA Label Image

Fig-v-f (Zarxio 23)

Fig-v-f (Zarxio 23)
An instructional line drawing showing a hand holding a vial while drawing liquid into a syringe. This illustration likely depicts how to prepare an injection dose of the drug. It is associated with ZARXIO (filgrastim-sndz) injection, solution.*
FDA Label Image

Fig-v-g (Zarxio 24)

Fig-v-g (Zarxio 24)
An instructional diagram showing a hand holding a syringe and drawing medication from a vial, illustrating proper technique for preparing an injection of medication, possibly filgrastim-sndz (ZARXIO).*
FDA Label Image

Fig-v-h (Zarxio 25)

Fig-v-h (Zarxio 25)
An anatomical diagram illustrating recommended injection sites on the human body for ZARXIO (filgrastim-sndz) injection, solution. Shaded areas highlight the upper outer arms, lower stomach area (abdomen), and front of the thighs as target sites for subcutaneous or intravenous administration.*
FDA Label Image

Fig-v-i (Zarxio 26)

Fig-v-i (Zarxio 26)
An anatomical illustration showing recommended injection sites for ZARXIO (filgrastim-sndz) injection. Shaded areas highlight the upper outer arms and the upper areas of the buttocks as appropriate injection locations on the human body outline.*
FDA Label Image

Fig-v-j (Zarxio 27)

Fig-v-j (Zarxio 27)
An instructional illustration showing the proper technique for injecting an injection solution. The image depicts a hand holding a syringe at a 45-degree angle and an instruction noting a 90-degree angle as a reference, indicating the angle for needle insertion into the skin of a forearm or hand.*
FDA Label Image

Fig-v-k (Zarxio 28)

Fig-v-k (Zarxio 28)
An instructional illustration showing a hand administering an injection with a syringe into the finger pad of the opposite hand. The syringe is held with the thumb and index finger, positioned for subcutaneous injection.*
FDA Label Image

Fig-v-l (Zarxio 29)

Fig-v-l (Zarxio 29)
An instructional illustration showing a medication vial and a syringe with arrows pointing toward a container, indicating the disposal or collection of materials used for injection administration.*
FDA Label Image

300mcg-label (Zarxio 30)

300mcg-label (Zarxio 30)
ZARXIO 300 mcg/0.5 mL injection label for filgrastim-sndz, a human prescription drug. The label states it is a single-dose prefilled syringe with a needle guard for intravenous or subcutaneous use only. It includes storage instructions to refrigerate and protect from freezing, and a caution about natural rubber latex. Manufactured by Sandoz Inc.*
FDA Label Image

480mcg-label (Zarxio 31)

480mcg-label (Zarxio 31)
ZARXIO 480 mcg/0.8 mL injection label for filgrastim-sndz, a human prescription drug by Sandoz Inc. The label states it is for subcutaneous and intravenous use only, single-dose vial, preservative-free, with warnings about freezing and latex caution. The label includes brand and generic names and dosage strength.*
FDA Label Image

300mcg-latexfree-1pkfb (Zarxio 300 1pk)

300mcg-latexfree-1pkfb (Zarxio 300 1pk)
ZARXIO (filgrastim-sndz) Injection 300 mcg/0.5 mL prefilled syringe label for subcutaneous or intravenous use. The label notes it is a recombinant Granulocyte Colony-Stimulating Factor derived from E. coli, no preservative, and that the syringe with safety guard is not made with natural rubber latex. Labeler is Sandoz Inc.*
FDA Label Image

Zarxio-480-1pkfb (Zarxio 480 1pk)

Zarxio-480-1pkfb (Zarxio 480 1pk)
ZARXIO (filgrastim-sndz) Injection, solution 480 mcg/0.8 mL prefilled syringe. For subcutaneous or intravenous use only. Contains a recombinant Granulocyte Colony-Stimulating Factor (rG-CSF) derived from E. coli, without preservative. The prefilled syringe includes a safety guard and is free of natural rubber latex. Labeler: Sandoz Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.